We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach.
- Authors
Gao, Ling; Lau, Yiu-Keung; Wei, Ran; O'Brien, Lisa; Long, Amanda; Piao, Yongzhe; Abada, Paolo
- Abstract
Purpose: We investigated the impact of infusion duration (30 and 60 min) on the pharmacokinetic profile of ramucirumab using a population pharmacokinetic (PopPK) modeling approach. We also assessed the relationship between infusion rate and incidence of immediate infusion-related reactions (IRRs; occurring on the day of administration) using ramucirumab phase II/III study data. Methods: The impact of different infusion durations (30 vs. 60 min) on the time-course of ramucirumab concentration profiles were evaluated using a PopPK model, established using ramucirumab pharmacokinetic data from 2522 patients. Logistic regression was used to evaluate the association between ramucirumab infusion rate and incidence of immediate IRRs in clinical trials. Results: Ramucirumab time-course concentration profiles were equivalent following a 30- or 60-min infusion. In the pooled clinical study dataset, 254 of 3216 (7.9%) patients receiving ramucirumab experienced at least one immediate IRR (any grade). When grouped according to infusion rate quartile, the incidence of immediate IRRs (any grade or grade ≥ 3) was similar across quartiles; findings were confirmed in sensitivity analyses. The risk of immediate IRRs was not found to be associated with infusion rate based on multivariate logistic analysis. Conclusion: Shortening the infusion duration of ramucirumab from 60 to 30 min has no impact on ramucirumab exposure. Analysis of trial data found no relationship between an increased risk of immediate IRRs and a faster infusion rate. Such a change in infusion duration is unlikely to affect the clinical efficacy or overall safety profile of ramucirumab.
- Subjects
VASCULAR endothelial growth factor antagonists; DRUG efficacy
- Publication
Cancer Chemotherapy & Pharmacology, 2021, Vol 87, Issue 5, p635
- ISSN
0344-5704
- Publication type
Academic Journal
- DOI
10.1007/s00280-020-04223-9